ABCD Study Results: Will Noninvasive T-Wave Test Boost ICD Referrals?
Data presented Nov. 15 helps validate microvolt t-wave alternans (MTWA) analysis for identifying certain patients at high risk for sudden cardiac death, but questions remain about the test's potential impact on physician practice
More from Archive
More from Medtech Insight
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.
The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.